Advanced Surgery Advantage
A data-driven, evidence-based haemostasis optimisation programme
The Burden of Bleeding
30%
Average rate of bleeding complications during surgery1
6 Days
Length of stay associated with bleeding-related complications or transfusions1
$10K+
Potential incremental cost of bleeding complications per patient hospitalisation for major surgeries1
The Challenge of Surgical Bleeding
Surgical bleeding can lead to complications and increased allogeneic blood utilisation creating headwinds to meeting your performance measures.
Surgical bleeds are associated with increased complication rates in1:
● Surgical revisions
● Transfusions
● Length of stay
● Increased resource utilisation
Focus on blood management protocols emphasising intraoperative interventions, including use of topical haemostatic agents, can help mitigate these challenges.
What Is Advanced Surgery Advantage?
Advanced Surgery Advantage is a data-driven, evidence-based haemostasis optimisation programme. It supports hospital initiatives aimed at:
● Reducing intraoperative blood loss
● Reducing blood transfusions
● Optimising patient outcomes after surgery
● Reducing waste
● Cost avoidance
It provides an approach to partnering with hospitals in support of their goals and quality initiatives.
Efficiencies in the Operating Room
Through Advanced Surgery Advantage, Baxter’s Advanced Surgery team partners with hospitals in support of their goals and quality programs. Advanced Surgery Advantage provides actionable insights and practical solutions related to intraoperative haemostasis that will help healthcare providers realise marked improvements in three, interconnected areas of surgical care:
● Clinical efficacy
● Financial performance
● Operational efficiency
Advanced Surgery Advantage offers several potential collaboration opportunities
Live Utilisation Review
To help hospitals assess their current state of hemostat utilisation, Baxter Medical Affairs conducts unbiased observation reviews of haemostat and sealant use, resulting in a detailed report of findings and improvement opportunities
Health Economic Assessment
To help hospitals quantify potential economic cost savings, Baxter Market Access works with hospitals to create a model to assess potential savings and measure results after implementing improvement opportunities
Patient Blood Management
To help hospitals assess the impact of implementing an intraoperative hemostasis protocol to reduce transfusions, Baxter Market Access supports operating room and blood bank staff in identifying clinical endpoints and evaluation criteria to measure the success of improvement initiatives
Portfolio of Products
Prescribing Information:
 |
Ireland TISSEEL |  |
Ireland ARTISS |
Suspected Adverse Reactions and any drug product quality complaints (including suspected defective medicines) should be reported to the Health Products Regulatory Authority (HPRA) using a Yellow Card obtained from the HPRA, via the online system (www.hpra.ie) or by telephone on 01-6764971.
Adverse Events relating to Baxter products can also be reported direct to Baxter Pharmacovigilance on +44 1635 206360, or by email to [email protected]
Any drug product quality complaints relating to Baxter products can be reported directly to the Baxter Country Quality Assurance Team on 01 2065500, or by email to [email protected]. Alternatively please report directly to your Baxter Representative, who will take the details and forward to the Baxter Country Quality Assurance Team.